
Please try another search
Vernalis Limited, a commercial stage pharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products for various medical disorders. The company offers Tuzistra XR for the U.S. prescription cough-cold market; Moxatag, a once-a-day formulation of amoxicillin antibiotic for the treatment of tonsillitis and pharyngitis secondary to streptococcus pyogenes in adults and pediatric patients; and frovatriptan for the acute treatment of migraine. It also holds licensing agreement to develop and commercialize various products focused on the U.S. prescription cough-cold market. Vernalis Limited was formerly known as Vernalis plc and changed its name to Vernalis Limited in October 2018. The company was incorporated in 1988 and is headquartered in London, United Kingdom. Vernalis Limited operates as a subsidiary of Ligand Pharmaceuticals Incorporated.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review